CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment

Excerpt from the Press Release:

SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ — CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its proprietary DNA Aptamer therapy, CGB-600, for the treatment of vitiligo.

The investigational active pharmaceutical ingredient, licensed from TAGCyx Biotechnologies Inc., Japan, is a first-in-class DNA Aptamer and new chemical entity specifically designed to selectively bind to interferon gamma and downregulate autoimmune activity implicated in the localized destruction of melanocytes. By targeting disease-specific immune pathways, CGB-600 aims to offer more durable re-pigmentation with fewer side effects compared to existing treatments.

“Vitiligo remains an area of high unmet medical need with limited durable treatment options” said Dr. Nitin Joshi, Chief Executive Officer of CAGE Bio. “Our DNA Aptamer program opens an entirely new therapeutic modality in immune-targeted skin therapeutics. Prior preclinical proof-of-concept studies suggest CGB-600 can achieve significant and sustained re-pigmentation. We believe this could be a transformative advancement for patients and providers.”

“Nucleic acids are large, charged molecules and their localized, topical delivery is a huge unmet need. This human clinical trial, where a drug of this size is being delivered non-invasively into the skin, is a major advancement in the drug delivery field”, said Dr. Samir Mitragotri, Professor of Bioengineering at Harvard University, who pioneered the ionic liquid drug delivery platform during his tenure at the University of California, Santa Barbara.

Click the button below to read the entire Press Release:

Continue Reading The Press Release